SCHEMBL19986477

SCHEMBL19986477

COC(=O)[C@H](Cc1ccc(OCOP(=O)(OC(C)(C)C)OC(C)(C)C)c(O)c1)NC(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KYNU Q16719 1/20 0.48
ALDH1A1 P00352 4/20 0.46
ALOX15 P16050 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ITGB3 P05106 2/20 0.43
ITGA2B P08514 2/20 0.43
LMNA P02545 1/20 0.42
F2 P00734 1/20 0.42
CTSL P07711 2/20 0.42
CTSB P07858 2/20 0.42
CTSS P25774 2/20 0.42
TYR P14679 1/20 0.42
CYP3A4 P08684 3/20 0.42
TSHR P16473 3/20 0.42
MAPT P10636 1/20 0.42
MDM4 O15151 1/20 0.41
MDM2 Q00987 1/20 0.41
TACR1 P25103 1/20 0.41
CTSK P43235 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17685910 0.91 KYNU (0.48) KYNUALDH1A1ALOX15MEN1KMT2A
SCHEMBL17685862 0.91 KYNU (0.48) KYNUALDH1A1ALOX15MEN1KMT2A
SCHEMBL17685911 0.91 KYNU (0.48) KYNUALDH1A1ALOX15MEN1KMT2A
SCHEMBL17693642 0.91 KYNU (0.48) KYNUALDH1A1ALOX15MEN1KMT2A
SCHEMBL17685861 0.91 KYNU (0.48) KYNUALDH1A1ALOX15MEN1KMT2A
SCHEMBL17693636 0.90 KYNU (0.48) KYNUALDH1A1ALOX15MEN1KMT2A
SCHEMBL17695787 0.88 MEN1 (0.46) KYNUALDH1A1ALOX15MEN1KMT2A
SCHEMBL17695789 0.88 MEN1 (0.46) KYNUALDH1A1ALOX15MEN1KMT2A
SCHEMBL28436612 0.85 ITGB3 (0.49) ALDH1A1ALOX15MEN1KMT2AITGB3
SCHEMBL28441360 0.85 ITGB3 (0.49) ALDH1A1ALOX15MEN1KMT2AITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180079762-A1 Carbidopa and L-Dopa Prodrugs and Methods of use ABBVIE INC. (US) 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079762-A1 Carbidopa and L-Dopa Prodrugs and Methods of use COMT, SNCA, PARK7 KYNU 126/4885ALDH1A1 694/4885ALOX15 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.